Fard SS and Holz MK. Regulation of mRNA Translation by Estrogen Receptor in Breast Cancer. Steroids. 2023. In press. https://doi.org/10.1016/j.steroids.2023.109316
Kundu N and Holz MK. Host-tumor interactions in Lymphangioleiomyomatosis, a rare metastatic lung disease. Am J Physiol Cell Physiol. 2023 Feb 1;324(2):C320-C326.
Gupta N, Zhang B, Zhou Y, McCormack FX, Ingledue R, Robbins N, Kopras EJ, McMahan S, Singla S, Jeffrey Swigris J, Cole AG, Holz MK. Safety and efficacy of combined resveratrol and sirolimus in lymphangioleiomyomatosis. Chest. 2023 Jan 13:S0012-3692(23)00041-7.
Nolan M, Knudson K, Holz MK, and Chaudhury I. Functional interaction between Fanconi anemia and mTOR pathways during stalled replication fork recovery. FEBS Lett. 2021; 595(5):595-603. doi: 10.1002/1873-3468.14035.
Torres AS, Holz MK. Unraveling the multifaceted nature of the nuclear function of mTOR. Biochim Biophys Acta Mol Cell Res. 2020; 1868(2):118907. doi: 10.1016/j.bbamcr.2020.118907.
Special issue: Emerging Concepts & Non-Canonical Pathways in Cellular Signaling
Faltas CL, Lebron KA, and Holz MK. Unconventional Estrogen Signaling in Health and Disease. Endocrinology 2020;161(4). pii: bqaa030. doi: 10.1210/endocr/bqaa030.
Cuesta R, Gritsenko MA, Petyuk VA, Shukla AK, Tsai CF, Liu T, McDermott JE, and Holz MK. Phosphoproteome Analysis Reveals Estrogen-ER pathway as a modulator of mTOR activity via DEPTOR. Molecular & Cellular Proteomics 2019;18(8):1607-1618.
Cuesta R, Berman AY, Alayev A, and Holz MK. Estrogen receptor α promotes protein synthesis by fine-tuning the expression of the eukaryotic translation initiation factor 3 subunit f (eIF3f). J Biol Chem. 2019; 294(7):2267-2278.
Bostner J, Alayev A, Berman AY, Fornander T, Nordenskjöld B, Holz MK and Stål O. Raptor localization and estrogen-dependent breast cancer growth. Breast Cancer Res and Treat. 2018; 168(1):17-27.
Berman AY, Motechin RA, Wiesenfeld MY, Holz MK. The therapeutic potential of resveratrol: a review of clinical trials. NPJ Precis Oncol, 2017; 1(35):1-9 doi:10.1038/s41698-017-0038-6
Berman AY, Manna S, Schwartz NS, Sun Y, Yu JJ, Behrmann CA, Plas DR, Alayev A, Holz MK. ERRα regulates the growth of triple-negative breast cancer cells via S6K1-dependent mechanism. Signal Transduct Target Ther. 2017;2. pii: e17035. doi: 10.1038/sigtrans.2017.35.
Li C, Liu Y, Zhang E, Sun Y, Li N, Medepalli K, Wikenheiser-Brokamp K, Plas DR, Sun J, Chen Y, Franz DN, Capal JK, Mays M, Kwiatkowski D, Alayev A, Holz MK, Kruger D, Siroky D and Yu JJ. Tuberin regulates prostaglandin E receptor 3-mediated viability of mTORC1-hyperactive cells via Rheb. Mol Cancer Res. 2017;15(10):1318-1330.
Alayev A, Salamon RS, Schwartz NS, Berman AY, Wiener SL, and Holz MK. Combination of Rapamycin and Resveratrol for Treatment of Bladder Cancer. J Cell Physiol. 2017; 232(2):436-446.
Alayev A, Salamon RS, Manna S, Schwartz NS, Berman AY, Holz MK. Estrogen induces RAD51C expression and localization to sites of DNA damage. Cell Cycle. 2016;15(23):3230-3239.
Cuesta R and Holz MK. RSK-mediated down-regulation of PDCD4 is required for the proliferation, survival, and migration in a model of triple-negative breast cancer. Oncotarget, 2016;7(19):27567-83.
Klionsky DJ et al., Guidelines for the Use and Interpretation of Assays for Monitoring Autophagy (3rd edition), Autophagy 2016;12(1):1-222.
Manna S. and Holz MK. Tamoxifen action in ER-negative breast cancer. Signal Transduction Insights 2016; 5, 1-
Alayev A, Salamon RS, Berger SM, Schwartz NS, Cuesta R, Snyder RB, Holz MK. mTORC1 directly phosphorylates and activates ERα upon estrogen stimulation. Oncogene. 2016; 35(27):3535-43
Manna S, Bostner J, Sun Y, Miller LD, Alayev A, Schwarz NS, Lager E, Fornander T, Nordenskjöld B, Yu JJ, Stål O, Holz MK. ERRa is a marker of tamoxifen response and survival in triple-negative breast cancer. Clin Cancer Res 2016; 22: 1421.
Alayev A, Berger SM and Holz MK. Resveratrol as a novel treatment for diseases with mTOR pathway hyperactivation. Ann. N.Y. Acad. Sci. 2015; 1348(1):116-23.
Alayev A, Salamon RS, Sun Y, Schwartz NS, Yu JJ, Holz MK. Effects of Combining Rapamycin and Resveratrol on Apoptosis and Growth of TSC2-Deficient Xenograft Tumors. Am. J. Respir. Cell Mol. Biol. 2015; 53(5), 637–646.
Pollack D, Xiao Y, Shrivastava V, Levy A, Andrusier M, D'Armiento JM, Holz MK, Vigodner M. CDK14 expression is down-regulated by cigarette smoke in vivo and in vitro. Toxicol. Lett. 2015; 234(2):120-30
Alayev A, Berger SM, Kramer MY, Schwartz NS, Holz MK. The combination of rapamycin and resveratrol blocks autophagy and induces apoptosis in breast cancer cells. J. Cell. Biochem. 2015; 116(3):450-7.
Alayev A, Doubleday PF, Berger SM, Ballif BA, Holz MK. Phosphoproteomics Reveals Resveratrol-
Dependent Inhibition of Akt/mTORC1/S6K1 Signaling. J. Proteome Res. 2014; 13(12):5734-42.
Alayev A, Sun Y, Snyder RB, Berger SM, Yu JJ, Holz MK. Resveratrol prevents rapamycin-induced upregulation of autophagy and selectively induces apoptosis in TSC2-deficient cells. Cell Cycle. 2014; 13(3):371-82.
Alayev A. and Holz MK. mTOR Signaling for Biological Control and Cancer. J. Cell. Physiol., 2013; 228: 1658–1664.
Holz, MK. The role of S6K1 in ER-positive breast cancer. Cell Cycle, 2012; 11(17):3159-65.
Maruani DM, Spiegel TN, Harris EN, Shachter AS, Unger HA, Herrero-González S, Holz MK. Estrogenic regulation of S6K1 expression creates a positive regulatory loop in control of breast cancer cell proliferation. Oncogene, 2012; 31(49):5073–5080.
Yamnik RL and Holz MK. mTOR/S6K1 and MAPK/RSK signaling pathways coordinately regulate estrogen receptor alpha serine 167 phosphorylation. FEBS Lett. 2010; 584(1):124-8.
Yamnik RL, Digilova A, Davis DC, Brodt ZN, Murphy CJ, Holz MK. S6 kinase 1 regulates estrogen receptor alpha in control of breast cancer cell proliferation. J Biol Chem. 2009; 284(10):6361-9.
Holz MK and Blenis J. (2008) Ribosomal protein S6 kinase beta-1 target assessment review. Targeted Proteins Database, Current Biodata. doi:10.2970/tpdb.2008.212.
Holz MK and Blenis J. (2008) Ribosomal protein S6 kinase beta-2 target assessment review. Targeted Proteins Database, Current Biodata. doi:10.2970/tpdb.2008.161.
Holz MK and Blenis J. (2008) Eukaryotic translation initiation factor 4E-binding protein 1 target assessment review. Targeted Proteins Database, Current Biodata. doi:10.2970/tpdb.2008.208.
Roux PP, Shahbazian D, Vu H, Holz MK, Cohen MS, Taunton J, Sonenberg N, Blenis J. RAS/ERK signaling promotes site-specific ribosomal protein S6 phosphorylation via RSK and stimulates cap-dependent translation. J Biol Chem. 2007; 282(19):14056-64.
Holz MK, Ballif BA, Gygi SP, Blenis J. mTOR and S6K1 mediate assembly of the translation preinitiation complex through dynamic protein interchange and ordered phosphorylation events. Cell. 2005; 123(4):569-80.
Holz MK and Blenis J. Identification of S6 kinase 1 as a novel mammalian target of rapamycin (mTOR)-phosphorylating kinase. J Biol Chem. 2005; 280(28):26089-93.